removing the cellular material by centrifugation, and adding metaphosphoric acid (MPA) to precipitate the proteins and prevent oxidation of the AA. The resulting suspension can then be stored at -80 #{176}C for extended periods (1-4) with no decrease in apparent AA content.
laboratory, removing the cellular material by centrifugation, and adding metaphosphoric acid (MPA) to precipitate the proteins and prevent oxidation of the AA. The resulting suspension can then be stored at -80 #{176}C for extended periods (1) (2) (3) (4) with no decrease in apparent AA content.
However, in routine laboratory procedures, 15 mm to several hours can elapse between blood sampling and treatment to stabilize AA, or between the thawing of a frozen specimen and its analysis. A significant loss of ascorbic acid content, and erroneous measurements of ascorbic acid in plasma, can result (6) . We confirmed the utility of dithiothreitol (DITI') as a preservative for AA in solution (7) , and demonstrated that dilute solutions of AA in acetonitrile:water (c) in plasma, when it is added with MPA (17 g/L final concentration). In addition we report two simple, rapid, accurate, and precise HPLC methods for determining AA in plasma that can be easily adapted for routine use by clinical chemistry laboratories.
Materials and Methods4
We used two independent HPLC analytical procedures. Method 1, performed at the National Bureau of Standards (NBS), was used to evaluate the stability of AA in DTFsupplemented human plasma samples. This procedure and a second procedure, method 2 (University of Arizona), were used to evaluate the stabilizing effects of DTF on patients' samples.
Method 1
AA, dehydroascorbic acid (DHAA), and D'ITFwere purchased from Sigma Chemical Co., St. Louis, MO. The acetonitrile was "IWLC" grade. The AA, examined by proton magnetic resonance, contained <0.1% impurities, including those related to AA or the degradation products of AA. Human plasma was prepared by Alpha Therapeutic Corporation and purchased from Western States Plasma Corp., Fallbrcok, CA, in 650-g lots. This plasma was obtained by plasmapheresis from human blood to which 50 mL of a solution of sodium citrate per 500 mL of blood (final concentration, 5 g/L) was added. The processed plasma was stored at -70 #{176}C until used.
In the stability studies, supplemented The supplemented plasma (lots 58-61) was prepared as follows: after slowly thawing a 650-g package of plasma at room temperature overnight, we removed any insoluble material by filtration through cheesecloth. This yielded 595 mL plasma, to which we added 611 mg DTr. The resulting solution was divided into four 148-mL lots. We supplemented three of the lots with AA by adding -0.3, 0.75, or 1.0 mL, respectively, of a 1.01 g/L AA stock solution. The fourth lot served as a blank for assessing the presence of possible substances interfering with the measurement methods. Each plasma lot was distributed in 1.3-mL volumes into 5-mL serum vials. The vials were then loosely capped with split serum stoppers, frozen, and freeze-dried. The stoppers, which were closed automatically after the samples were completely freeze-dried and the vacuum had been released, were secured with metal caps and stored at either -25 or -80 #{176}C. The process of filtering, supplementing, sampling, and freezing was completed within 3 h. Each sample could 'IdentifIcation of any commercial product does not imply recommendation or endorsement by the National Bureau of Standards, nor does it imply that the material or equipment identified is necessarily the best available for the purpose. be reconstituted to its original volume by adding 1.2 mL of distilled water.
To extract the AA from the freeze-dried plasma samples we added 1.5 mL of distilled water to each sample. After the material completely dissolved, we transferred the entire solution to a 4-mL screw-cap vial containing 160 L of 400 g/L aqueous MPA, capped the vial, and vortex-mixed for 15 s. We then added 400 pL of HPLC-grade acetonitrile, capped the sample, and vortex-mixed for 15 s. (This step improved protein aggregation and prevented precipitation of material on the top of the HPLC column.) After centrifuging the resulting suspension (1000 x g, 30 mm, 4#{176}C), we transferred the supernatant fluid to 1.8-mL vials, placed them in an autosampler, and flushed 300 p.L of sample through a 20-pL sampling loop (to eliminate carryover from the previous sample).
The samples were analyzed by a modification of the method of Grun and Loewus (6) with a 300 x 7.8 mm Aminex HPX87H cation-exchange column (Bio-Rad Laboratories, Richmond, CA). The column was equilibrated at 30#{176}C with 0.1 moJJL formic acid containing 50 mL of acetonitrile per liter, at a flow rate of 0.5 mL/min. We added the acetonitrile to prevent bacterial growth and improve peak shape.
The chromatogram was developed isocratically and the eluted components were detected spectrophotometrically at 265 nm and electrochemically at +0.7 V, in the oxidation mode. The amount of AA was determined by peak-height measurement (electrochemical determinations) and by peak integration (ultraviolet absorbance and electrochemical determinations).
Method 2
Ascorbic acid ("Gold Label") was purchased from Aldrich Chemical Co., Milwaukee, WI. D'VF, EDTA, chloroacetic acid, and MPA were purchased from Sigma Chemical Co. Octyl sodium sulfate was purchased from Eastman Kodak Co., Rochester, NY.
The or unsupplemented plasma to a 1.5-mL "microfuge" tube containing 900 p.L of a cold, freshly prepared solution of MPA (30 g/L) and DTF (1 g/L). After standing 10 mm, the samples were centrifuged (15 mm, 11 600 x g) and a 25-pL portion of the supernate was analyzed by HPLC.
Clinical samples of human plasma were prepared for storage at -70 #{176}C by adding 100 /.LL of plasma to 300 p.L of the MPA/DTF solution, mixing, and promptly freezing at -70 #{176}C. At the time of analysis we added 600 p.L of a freshly prepared 30 g/L solution of MPA to the sample, thawed the sample, mixed well, centrifuged (11 600 x g, 15 mm), and analyzed 25 pL of the supernate by HPLC.
The analytical column and the electrochemical detector were conditioned (passivated) with an aqueous solution of Na4EDTA (2.55 gIL) at a flow rate of 1 mL/min for 30 mm before analyzing for AA. We used isocratic elution at a flow rate of 0.5 mL/min at ambient temperature with a column that was equilibrated with a mobile phase consisting of 14.1 g of chioroacetic acid, 4.65 g of NaOH, 0.85 g of Na4EDTA, and 200 mg of octyl sodium sulfate in 1 L of distilled water. The electrochemical detector was set at +0.7 V and the amount of AA was quantified by peak-height measurement and electronic peak integration.
The plasma samples for use in the study comparing methods 1 and 2 were processed within 1 h. We drew 15 mL of blood into heparinized, foil-wrapped tubes and centrifuged immediately.
Seven milliliters of plasma was promptly removed and 250 pL of a solution containing 1.2 mg D'YF (final concentration, 0.17 g/L) and 125 mg MPA (final concentration, 17.2 g/L) was added. The samples, divided into 1.3-mL aliquots, were stored at -80 #{176}C until analyzed.
For analysis by method 1, we added 1.3 mL of sample to 160 p.L of a 400 g/L solution of MPA and mixed for 15s, then added 400 pL of acetonitrile, mixed for 15 s, centrifuged, and analyzed the supernatant fluid for AA as described above. For analysis by method 2 the protocol previously described was followed. Each of the split samples from each patient was analyzed in duplicate.
Results
The utilization of DTT as an antioxidant for AA has been well documented (3, 7, 8). Recent studies at NBS demonstrated that DVI' is also an effective long-term preservative for AA (3). In some of the analyses for AA by HPLC (3,8) an aminosilane column was used, which resolved AA and Drr.
We found it difficult to obtain reproducible chromatographic separations with different aminosilane columns. We also found it difficult to prevent degradation of the AA during the separation process on an aminosilane column without resorting to elaborate sparging and the use of antioxidants in the HPLC solvent (3). We circumvented these problems by using the HPX87H or an ODS 5-pm particle column. AA is not destroyed on these columns and AA is resolved from MPA, uric acid, and DTI', all of which produce an electrochemical response and could contribute to errors in measurement if they are not completely separated from AA.
Measurement of AA in plasma with an ultraviolet detector is difficult because there are several intense ultravioletabsorbing peaks that elute very close to AA, and large amounts of sample must be used in order to obtain a sufficient signal for AA quantification. The use of an electrochemical detector results in increased sensitivity and selectivity (9) as compared with the ultraviolet technique. However, the DTF also has a strong electrochemical signal at the same voltage as AA (3). Because in our experience some ionpairing methods do not adequately resolve D'VI'from AA, it was necessary to select an HPLC method of analysis that would resolve these compounds. Methods 1 and 2 both give baseline resolution between uric acid, DTF, and AA (Figures 1 and 2) , and method 1 also resolves two additional trace materials (Figure 1 ) that are present in AA-depleted plasma.
The range and sensitivity of the electrochemical method 
Stability of the Ascorbic Acid during Automated Analysis
All of the analyses done by method 1 were performed with an autosampler during -24 h. Under these conditions, the stability of AA at room temperature becomes important (1, 2, 10). We evaluated this variable by measuring the area of the chromatographic peaks absorbing in the ultraviolet seen on chromatographing standard solutions containing DTF. For periods up to 18 h, little or no deterioration of the standard AA solutions at 21#{176}C was detected, an observation supported by the fact that the relation between the concentration of AA and the area of the AA HPLC peak was linear from 2 to 20 mgfL and closely approached the origin (slope = 49124 arb. units, intercept = 817, r2 = 0.9999, n = 6). When stored at 4#{176}C, these solutions remained stable for several weeks, after which new standards were prepared.
For standards stored at 4#{176}C (method 2) the AA measured remained constant for the duration of the experiment. The concentration curve for these standard solutions was linear from 5 to 20 mgfL, intersecting the origin with a slope of 57.900 and a correlation coefficient of 0.9992. The standards and samples analyzed by this method were never stored at room temperature. A. standard solutions;B, human plasma. Peak identityas in Fig. 1 
Stability of the Electrochemical Detector
Of primary consideration was the time-dependent variation in the sensitivity of the electrochemical detector. Method 1 was characterized by a time-dependent decrease in the detector sensitivity, which varied from one analysis to another. This was demonstrated by measuring, in duplicate, a series of standards (three different concentrations) at the beginning and at the end of an experiment.
Each set of measurements was plotted separately.
The ultraviolet absorbance of the standards remained constant throughout the experiment (Figure 3B) , whereas the electrochemical response decreased by a constant value over the entire concentration range, resulting in parallel curves displaced by a constant value ( Figure 3A) . Additionally, the standard of intermediate concentration (4.2 mg/L) was assayed after every two plasma samples (three additional times), and the results decreased steadily throughout the experiment, indicating a continuous change in the sensitivity of the electrochemical detector.
In contrast, method 2 was characterized by a timedependent increase in detector sensitivity; that is, the slope of the standard curve increased and the intercept remained constant over a 4-h period ( Figure 3C ). Thus, for both methods, frequent standards were run, to correct for variations in response of the electrochemical detector.
Stability of Ascorbic Acid in Human Plasma Supplemented with Dithiothreitol
Okamura (7) demonstrated that DTF reduces DHAA, so that total AA in plasma can be measured. To test the utility of using this reagent for reducing plasma DHAA and preserving plasma AA for extended periods of time, we modified pools of AA-depleted human plasma by adding DTF to give a concentration of 1 g/L (5.3 mmolIL) and subsequently supplemented with AA to give concentrations between 2 and 16 mg/L in plasma. Both freeze-dried and frozen supplemented 1.3-mL samples of plasma were prepared from these pools and stored at -80#{176}C for as long as 18.5 months. The AA content of these samples, measured at the indicated time intervals, is summarized in Table 1 . Randomly selected samples from each of lots 37, 38,45, and 46 were analyzed in duplicate at the time intervals indicated in Table 1 . These values were within one standard 
h; x---x, 18 h
deviation of the amount gravimetrically added to the original plasma pool. This indicates that the AA is not oxidized in the presence of D'I'F under these storage conditions. Lots 58-61 constituted a second group of samples, which was prepared and freeze-dried. This group included an unsupplemented poo1 of plasma and three poo1s of plasma supplemented to contain -2, 4.8, and 6.7 mg of added AA per liter of plasma. Four samples from each pool were analyzed in duplicate two weeks after the samples were prepared, to confirm the initial AA concentration. The plasma AA concentration of samples randomly selected from these pools was also measured at the time intervals indicated in Table  1 . The results complement and support the conclusion that DTF indeed protects and preserves the integrity of AA in human plasma for at least 66 weeks when stored at -80 #{176}C. Finally, AA was never detected in any of the unsupplemented plasma samples (lot 59, Figure l#{192}) .
The utility of this method for preparing reference materials for the measurement of AA in plasma is further supported by the results obtained in two unpublished collaborative studies (lots 37, 45, and 46; and lots 58, 60, and 61) cosponsored by NBS and The National Cancer Institute ( Table  2) . The values reported in these collaborative studies, which were obtained with a variety of methods, show acceptable agreement with the measurements made at NBS. tion is complete within 60 mm (compare the 1-and 4-h values in Table 3 ). If MPA is added to the D'ITFbefore the plasma is added, the reduction still occurs (Table 2 and Figure 4) . Thus by measuring the AA both before and after addition of the reducing agent, DTF, it is possible to measure the AA and DHAA differentially in biological samples by an electrochemical method. However, it is still impossible to determine by this method whether the DHAA was initially present in the plasma or was formed during removal of the blood cells. We evaluated the effect of DTF on AA in blood by collecting into heparinized tubes two blood samples from a patient with very low concentrations of AA in his plasma. One of the blood samples (9.5 mL) was collected into 0.5 mL of a solution containing 15 mg D'VF; the other blood sample served as a control. AA was added to each blood sample to give a concentration of 7 mg/L, the plasma was prepared, and the Alt was measured by method 2. Table 4 . The CV for these determinations was between 0.1% (subject 1) and 5.3% (subject 10). The size of the standard deviation does not appear to be concentration dependent (compare subject 1 with 9) or method dependent (same subjects). Furthermore, the samples appear to be stable for no less than 52 days, thus establishing the utility of this method for collecting and storing patients' plasma for Alt measurement.
Mechanism of Action of DTT

Discussion
Measuring AA in plasma is useful in the diagnosis of deficiency syndromes, the assessment of human nutritional status, and in confirming subject adherence (compliance) to experimental protocols such as chemoprevention and chemotherapy studies (13). For large, multilaboratory studies, it is essential to have suitable stable reference materials to assess the quality control, precision, and accuracy of participating laboratories. The human plasma reference material that we describe here can be prepared by a central laboratory for the assessment of interlaboratory and intralaboratory performance or can be prepared in the individual laboratory and used for an extended period of time to assess intralaboratory quality control.
The use of reducing agents to convert DHAA to AA is well documented, particularly with respect to methods in which the AA was derivatized before spectrophotometric measurement (12) as well as techniques involving HPLC (3,4,8,11) . The utility of IYVF as a reducing agent for DHAA in plasma was demonstrated by Okamura (7) and used for the measurement of AA in fruit juices (4,8) and urine (8). Okamura (7) noted that among the reducing agents tested, DTF exhibited reducing activity over a broader pH range than the other compounds examined, and in aqueous solution it was more stable than other reducing agents. It was superior to glutathione, mercaptoethanol, cysteine, homocysteine, and 2,3-dimercapto-1-propanol.
By using DTF to convert DHAA to AA, Okamura was able to measure differentially DHAA and total plasma AA by assaying Alt in the presence and absence of D'lT. Since then, DTF was shown to be an effective antioxidant for the long-term preservation of AA in aqueous organic solution (3). These observations were extended to include plasma, which can be stored in the presence of DTF for more than one year at -80 #{176}C without the Alt undergoing any oxidation (Table 1 ). Blood can also be collected into a solution of DTF without causing coagulation. Therefore, DF can be introduced immediately at the time of blood sampling, thus preventing any oxidation of Alt, either during the process of removal of blood cells or during subsequent storage. However, this procedure precludes the measurement of any native DHAA.
The differential content of DHAA and Alt can be determined by first obtaining the plasma, treating it with MPA to stabilize it, and then measuring the plasma AA both in the absence and presence of DTP. The difference between these measurements represents the DHA.A content. This follows from the observation that in the presence of MPA (20 g/L) and DTF (1 g/L), DHAA in plasma is converted to AA (Table 3 and Figure 4 ). This type of experiment was done with fruit juice (4, 8, 11) and urine (8) .
The measurement of total AA in plasma preserved at -80 #{176}C in DTF (170 mg/L) plus MPA (20 gIL) and the stability of clinical samples preserved in this manner was evaluated on split samples from 11 subjects. The samples were stable for 52 days (Table 4 ) and detectable amounts of DTF were still present in the sample ( Figure 1C) . We did not observe any significant consistent variation in the Alt content of these samples, and these observations are consistent with the results reported by other investigators (1, 4) . Thus DTF prevents oxidation of AA in blood samples without causing coagulation (at a concentration of 1 gIL), and in plasma for extended periods of time in the presence or absence of MPA and in either the frozen or freeze-dried state.
All of the colorimetric methods are based on either the direct oxidation of Alt by a colorimetric reagent or the oxidation of Alt to DHAA and the subsequent derivatization of DHAA to a material that can be measured colorimetrically (12). The lack of total specificity of these reactions can lead to significant errors in measurement.
Because all of these methods involve the measurement of a reduced form of AA, the presence of relatively large amounts of a reducing agent (D'Yl') can introduce a significant error. Okamura (7) solved this problem by reducing his AA samples with sulfhydryl reagents and then removing the sulfhydryl reagents by treating his samples with N-ethylmaleimide. Thus, reference Alt samples treated with DVI' can be used as standards for some colorimetric Alt assays if the samples are first treated with a sulfhydryl reagent such as Nethylmaleimide.
Using IiPLC methods in conjunction with electrochemical detectors improves selectivity of Alt determinations (8). The increase in selectivity as well as sensitivity over the ultraviolet detectors can be seen in the dual recording in Figures  1 and 4 . It is apparent that the Alt signal is not well resolved from other ultraviolet peaks, whereas baseline resolution was observed with electrochemical detection. Furthermore, the electrochemical method permits increases in sensitivity of at least two orders of magnitude as is demonstrated by method 2 (Figure 2) .
The three HPLC methods that were used to analyze AA in the presence of DTF were chosen because they resolve D'YF from Alt. These include analysis on an aminosilane column in a previous study (3), an HPX87H column (method 1), and a reversed-phase column (method 2). Each of these systems resolves DTF, uric acid, and metaphosphoric acid from Alt.
We were unable to obtain consistent results with different aminosilane columns and therefore, have adopted the two methods described herein.
Both HPLC methods are capable of measuring accurately the AA concentration in gravimetrically supplemented samples (37, 38,45, and 46). The accuracy of these two methods was compared by analyzing the reference samples described in Tables 1 and 2 . The results are in good agreement, and because the unsupplemented plasma contained no electrochemically detectable material with the retention time of AA, these results indicate that both methods accurately measure the Alt in plasma. Furthermore, the use of two independent methods that are based on different mechanisms of separation (ion exchange vs paired ion chromatography) lends credence to the accuracy of the measurement and decreases the probability that interfering substances are present in the analyte peak.
With the knowledge that these methods were accurate within the limits of the two methods and that DF reduced 
